EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants’ Full-Length Spikes in a Multiplex Luminex Assay

Gerald Waweru, Ruth Nyakundi, Bernadette Kutima, Sharon Owuor, Gloria Konyino, John Gitonga, Doreen Lugano, Angela Maina iD, Jennifer Musyoki, Lucy Ochola iD, Martin Omondi iD, Christopher K Kariuki iD und 13 weitere

Viruses · 2025

DOI: 10.3390/v17091248 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Viruses, 2025. Verfasst von Gerald Waweru und 24 weiteren Autor:innen. Beteiligte Einrichtung: KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast, Kilifi P.O. Box 230-80108, Kenya. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, SARS-CoV-2, Antibodies, Viral, COVID-19. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gates Foundation, National Research Fund Kenya, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to evolve, with mutations leading to the emergence of new variants. JN.1, a subvariant of omicron BA.2.86, has demonstrated marked immune escape and is now included in updated vaccine formulations. While reduced sensitivity has been reported for antibody assays using ancestral spike protein subunits to detect omicron-induced responses, the performance of full-length spike-based assays against omicron sublineages remains unclear. We aimed to compare the sensitivity of ELISA and Luminex assays using full-length spike proteins from the ancestral Wuhan strain and the JN.1 variant.

Methods

Wuhan and JN.1 full-length spike protein constructs were designed and expressed in Expi293F mammalian cells. In-house ELISAs based on previously validated protocols were used to measure anti-spike IgG levels. Additionally, a Luminex-based assay for anti-spike antibody detection was developed and validated. Both assays were applied to the following sample groups: pre-pandemic samples (designated “gold standard negatives”); PCR confirmed 2020 positives (“gold standard wildtype positives”); PCR confirmed 2024 positives (“gold standard omicron positives”); 2022 vaccinated individuals with verbal confirmed infection (“gold standard hybrid positives”); and 2024 household samples (“unknowns”).

Results

Wuhan spike protein showed a sensitivity of 100% (95% CI: 0.88–1.0) in detecting omicron-specific antibodies using gold standard omicron positives with JN.1 spike protein as a reference assay. Overall, across all samples, in ELISA, the Wuhan antigen had a sensitivity of 0.93 (95% CI: 0.89–0.95) and a specificity of 0.98 (95% CI: 0.94–0.99). The JN.1 antigen showed a sensitivity of 0.91 (95% CI: 0.87–0.94) and a specificity of 0.97 (95% CI: 0.93–0.99). In Luminex, sensitivity was 0.95 (95% CI: 0.91–0.97) for Wuhan and 0.94 (95% CI: 0.91–0.96) for JN.1. Specificity for both antigens in Luminex was 0.98 (95% CI: 0.94–0.99).

Conclusions

Both ELISA and Luminex assays showed comparable sensitivity and specificity for both Wuhan and JN.1 antigens, indicating that mutations in the JN.1 variant do not significantly impact assay performance. This suggests preserved antigenic recognition across variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusSARS-CoV-2Antibodies, ViralCOVID-19HumansMutationEnzyme-Linked Immunosorbent AssaySensitivity and SpecificityImmunoglobulin GCOVID-19 Serological Testing

Stichwörter der Autor:innen

ELISALuminexSARS-CoV-2agreementomicronsensitivityspecificitywildtype

Substanzen

Spike Glycoprotein, CoronavirusAntibodies, Viralspike protein, SARS-CoV-2Immunoglobulin G

Autor:innen und Institutionen

  • KEMRI-Wellcome Trust Research Programme, Center for Geographic Medicine Research, Coast, Kilifi P.O. Box 230-80108, Kenya.
  • School of Pure and Applied Sciences, Department of Biological Sciences, Pwani University, Kilifi P.O. Box 195-80108, Kenya.
  • Kenya Institute of Primate Research, Nairobi P.O. Box 24481 00502, Kenya.
  • Kenya Medical Research Institute, Nairobi P.O. Box 54840 00200, Kenya.
  • Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
  • Nuffield Department of Medicine, Oxford University, Oxford OX3 7BN, UK.

ORCID-Profile: Angela Maina, Lucy Ochola, Martin Omondi, Christopher K Kariuki, Paul Ogongo, Faiz Shee, Sophie Uyoga, James Nyagwange

Förderung

  • Gates Foundation
  • National Research Fund Kenya
  • Wellcome Trust
  • National Research Fund, Kenya
  • Bill and Melinda Gates Foundation

Zitieren

APA

Waweru, G., Nyakundi, R., Kutima, B., Owuor, S., Konyino, G., Gitonga, J., Lugano, D., Maina, A., Musyoki, J., Ochola, L., Omondi, M., Kariuki, C. K., Ogongo, P., Mwachari, C., Shee, F., Agoti, C., Sande, C., Uyoga, S., Kagucia, E., …, & Nyagwange, J. (2025). Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants’ Full-Length Spikes in a Multiplex Luminex Assay. Viruses. https://doi.org/10.3390/v17091248

Vancouver

Waweru G, Nyakundi R, Kutima B, Owuor S, Konyino G, Gitonga J, et al. Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants’ Full-Length Spikes in a Multiplex Luminex Assay. Viruses. 2025. doi:10.3390/v17091248

BibTeX
@article{Waweru2025,
  author = {Waweru, Gerald and Nyakundi, Ruth and Kutima, Bernadette and Owuor, Sharon and Konyino, Gloria and Gitonga, John and Lugano, Doreen and Maina, Angela and Musyoki, Jennifer and Ochola, Lucy and Omondi, Martin and Kariuki, Christopher K and Ogongo, Paul and Mwachari, Christina and Shee, Faiz and Agoti, Charles and Sande, Charles and Uyoga, Sophie and Kagucia, Eunice and Agweyu, Ambrose and Bejon, Philip and Scott, J Anthony G and Warimwe, George M and Ochola-Oyier, L Isabella and Nyagwange, James},
  title = {Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants’ Full-Length Spikes in a Multiplex Luminex Assay},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17091248}
}
Kostenlos starten →